Journal of Pharmacy and Pharmaceutical Sciences

Papers
(The TQCC of Journal of Pharmacy and Pharmaceutical Sciences is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Progress and Prospects of Research Ideas and Methods in the Network Pharmacology of Traditional Chinese Medicine52
Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis51
Epithelial and Endothelial Expressions of ACE2: SARS-CoV-2 Entry Routes43
Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India40
Pyrrole as an Important Scaffold of Anticancer Drugs: Recent Advances37
Monkeypox: Virology, Pathophysiology, Clinical Characteristics, Epidemiology, Vaccines, Diagnosis, and Treatments34
Solid Lipid Nanoparticles: An Approach to Improve Oral Drug Delivery30
Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis21
Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study20
Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions19
Pharmacovigilance Evaluation of Bendamustine-related Skin Disorders using the Japanese Adverse Drug Event Report Database16
Recent Advances in Oral Mucoadhesive Drug Delivery15
Health Canada Usage of Real World Evidence (RWE) in Regulatory Decision Making compared with FDA/EMA usage based on publicly available information15
Association Between Vitamin D Levels and Inflammatory Markers in COVID-19 Patients: A Meta-Analysis of Observational Studies15
The Lymphatic System: A Sometimes-Forgotten Compartment in Pharmaceutical Sciences13
Losartan Inhibits SARS-CoV-2 Replication in Vitro11
Periostin: A Potential Biomarker and Therapeutic Target in Pulmonary Diseases11
Naproxen for Post-Operative Pain11
Genotype-Guided Antiplatelet Therapy Versus Standard Therapy for Patients with Coronary Artery Disease: An Updated Systematic Review and Meta-Analysis11
Effects of Vitamin D Serum Level on Morbidity and Mortality in Patients with COVID-19: A Systematic Review and Meta-Analysis11
Adapting artificial intelligence into the evolution of pharmaceutical sciences and publishing: Technological darwinism10
ADVANCES OF NON-IRON METAL NANOPARTICLES IN BIOMEDICINE10
Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis10
The CYP2R1 Enzyme: Structure, Function, Enzymatic Properties and Genetic Polymorphism10
Research progress on vesicle cycle and neurological disorders10
The Association Between the Risk of Hypertensive Disorders of Pregnancy and Folic Acid: A Systematic Review and Meta-Analysis9
Applications of Exhaled Breath Condensate Analysis for Drug Monitoring and Bioequivalence Study of Inhaled Drugs9
miR-484: A Possible Indicator of Drug-Induced Pulmonary Fibrosis8
Torsade de Pointes/QT Prolongation Associated with Antifungal Triazoles: A Pharmacovigilance Study Based on the U.S. FDA Adverse Event Reporting System（FAERS）7
Integration of real-world evidence from different data sources in health technology assessment7
Synthesis of New Hybrid Derivatives from Metronidazole and Eugenol Analogues as Trypanocidal Agents7
Effectiveness of pulse dose methyl prednisolone in management of COVID 19: A systematic review and meta-analysis of observational studies.7
Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System7
Network pharmacology and molecular docking reveal the immunomodulatory mechanism of rhubarb peony decoction for the treatment of ulcerative colitis and irritable bowel syndrome6
The role of CYP2C9*2, CYP2C9*3 and VKORC1-1639 variants on the susceptibility of upper gastrointestinal bleeding: A full case-control study6
Persistence and switching patterns of migraine prophylactic medications in Canada: A retrospective claims analysis comparing adherence and evaluating the economic burden of illness6
0.057925939559937